Abstract:Objective: To compare the diagnostic efficacy of AI-guided mpMRI-TRUS fusion assisted transperineal systematic biopsy, targeted biopsy and combined biopsy in the diagnosis of PCa, and to evaluate the clinical application value of combined biopsy. Methods: From April 2022, the general personal information and clinical data of patients with suspicious prostate lesions (PI-RADS≥3) detected by 3.0T mpMRI were collected, then underwent AI-guided mpMRI-TRUS fusion-assisted transperineal prostate biopsy. The data included age, PSA level, PV, PSAD, PI-RADS score, Gleason score of biopsy tissue, etc. The mpMRI image data were imported into the real-time fusion imaging system before biopsy. After image fusion, the suspected PCa lesion was taken as the target, 2 to 3 cores of targeted biopsy were first performed, then 12 cores of systematic biopsy were continued. The results of targeted biopsy + systematic biopsy were defined as the results of combined biopsy. The detection rate of PCa, CsPCa and pathological Gleason score were compared among different biopsy methods, and the diagnostic efficacy in different PI-RADS score groups was further evaluated. Results: A total of 118 PCa cases were detected in 220 patients enrolled in this study. The PCa detection rates of systematic biopsy and targeted biopsy were 40.45% and 43.64%, the result reveals no statistical significance (P=0.562). The PCa detection rate of combined biopsy was 53.64%, higher than single biopsy method and the differences were statistically significant (P<0.05). The detection rates of CsPCa in systematic biopsy and targeted biopsy were 28.18% and 37.27% which reveals significant statistical difference (P=0.042). The CsPCa detection rate of combined biopsy was 41.82%, higher than single biopsy method, the difference was statistically significant compared with systematic biopsy (P=0.003), but was not compared with targeted biopsy (P=0.330). In PI-RADS score 3 group, the PCa detection rate of systematic biopsy and targeted biopsy was 39.29% and 21.43%, which reveals no statistical significance (P=0.146). The PCa detection rate of combined biopsy was 50%, higher than single biopsy method, the difference was statistically significant compared with targeted biopsy (P=0.026), but was not compared with systematic biopsy (P=0.420). In PI-RADS 4 ~5 group, the PCa detection rate of systematic biopsy and targeted biopsy was 40.10%, and 46.88% which reveals no statistical significance (P=0.181). The PCa detection rate of combined biopsy was 54.17%, higher than single biopsy method, the difference was statistically significant compared with systematic biopsy (P=0.006), but was not compared with targeted biopsy (P=0.153). Among PCa patients detected by both systematic and targeted biopsy, 39 had concordant pathologic Gleason scores, 13 had escalating pathologic Gleason scores for systematic biopsy, and 18 had escalating pathologic Gleason scores for targeted biopsy. Conclusion: Compared with systematic biopsy, AI-guided mpMRI-TRUS image fusion assisted transperineal targeted prostate biopsy has a higher detection rate of CsPCa and is probably closer to the true pathological Gleason score. Compared with single biopsy, combined biopsy has higher diagnostic efficiency for PCa, which can be used as one of the options of prostate biopsy in clinical practice.

Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study

Can 3D Multiparametric Ultrasound Imaging Predict Prostate Biopsy Outcome?

3-D Multi-parametric Contrast-Enhanced Ultrasound for the Prediction of Prostate Cancer.

Machine Learning for the Prediction of Prostate Cancer Biopsy Based on 3D Dynamic Contrast-Enhanced Ultrasound Quantification

AI-predicted Mpmri Image Features for the Prediction of Clinically Significant Prostate Cancer.

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm

Three-dimensional Convolutional Neural Network Model to Identify Clinically Significant Prostate Cancer in Transrectal Ultrasound Videos: a Prospective, Multi-Institutional, Diagnostic Study

Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence

Using an Artificial Intelligence Model to Detect and Localize Visible Clinically Significant Prostate Cancer in Prostate Magnetic Resonance Imaging: a Multicenter External Validation Study.

Biopsy-free prediction of prostate cancer aggressiveness using deep learning and radiology imaging

Artificial intelligence is a promising prospect for the detection of prostate cancer extracapsular extension with mpMRI: a two-center comparative study

Association between artificial intelligence–derived tumor volume and oncologic outcomes in localized prostate cancer.

Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept

Multimodal AI Combining Clinical and Imaging Inputs Improves Prostate Cancer Detection

PI-RADSAI: Introducing a New Human-in-the-loop AI Model for Prostate Cancer Diagnosis Based on MRI

Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent

Performance of Artificial Intelligence-Aided Diagnosis System for Clinically Significant Prostate Cancer with MRI: A Diagnostic Comparison Study

The Added Value of AI-based Computer-Aided Diagnosis in Classification of Cancer at Prostate MRI

[Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy]

[Application of Artificial Intelligence Combined with Multi-Parametric MRI in the Early Diagnosis of Prostate Cancer].

Deep‐Learning‐Based Artificial Intelligence for PI‐RADS Classification to Assist Multiparametric Prostate MRI Interpretation: A Development Study